AlbertF.LoBuglioMD
Oncology • Birmingham, ALProfessor, Medicine, University of Alabama School of Medicine
Are you Dr. LoBuglio?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 34 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
1802 6th Ave S
Np 2556
Birmingham, AL 35233Phone+1 205-934-5077Fax+1 205-975-7428
Summary
- Dr. Albert LoBuglio, MD is an oncologist in Birmingham, Alabama. He is currently licensed to practice medicine in Alabama. He is a Professor at University of Alabama School of Medicine.
Education & Training
Boston University Medical CenterResidency, Internal Medicine, 1965 - 1967
UPMC Medical EducationResidency, Internal Medicine, 1963 - 1965- UPMC Medical EducationInternship, Transitional Year, 1962 - 1963
Georgetown University School of MedicineClass of 1962
Certifications & Licensure
AL State Medical License 1983 - 2015
Awards, Honors, & Recognition
- Elected Member The American Society for Clinical Investigation, 1974
Clinical Trials
- Cetuximab and Irinotecan in Treating Patients With Advanced Colorectal Cancer Start of enrollment: 1999 Oct 01
- Cetuximab Plus Gemcitabine in Treating Patients With Locally Advanced, Metastatic, or Recurrent Cancer of the Pancreas Start of enrollment: 1999 Oct 01
Publications & Presentations
PubMed
- 47 citationsHER2 Overexpression Renders Human Breast Cancers Sensitive to PARP Inhibition Independently of Any Defect in Homologous Recombination DNA RepairSomaira Nowsheen, Tiffiny Cooper, James A. Bonner, Albert F. LoBuglio, Eddy S. Yang
Cancer Research. 2012-09-15 - 11 citationsTrastuzumab-Resistant HER2+ Breast Cancer Cells Retain Sensitivity to Poly (ADP-Ribose) Polymerase (PARP) InhibitionMonica E. Wielgos, Zhuo Zhang, Rajani Rajbhandari, Tiffiny S. Cooper, Ling Zeng
Molecular Cancer Therapeutics. 2018-03-28 - 134 citationsExpression of human endogenous retrovirus k envelope transcripts in human breast cancer.Feng Wang-Johanning, Andra R. Frost, Gary L. Johanning, M. B. Khazaeli, Albert F. LoBuglio
Clinical Cancer Research. 2001-06-01
Press Mentions
Closing the GapNovember 3rd, 2022- Cancer Disparities Through the DecadesJune 10th, 2022
Personalized Medicine: UAB Breast Cancer Research Works Toward Focused TreatmentsOctober 6th, 2016
Grant Support
- Comprehensive Cancer Center Core Support GrantNational Cancer Institute1995–2003
- Novel Radioimmunotherapy For Ovarian CancerNational Cancer Institute2000–2002
- Targeted Immunotherapy ProgramNational Cancer Institute1999–2002
- Interferon Enhanced Intraperitoneal Radioimmunity For Ovarian CancerNational Center For Research Resources1997–2002
- Rituxan In Treatment Of Immune Thrombocytopenic PurpuraNational Center For Research Resources2000
- Idec-Y902b8 Radioimmunotherapy: Relapsed B Cell LymphomaNational Center For Research Resources2000
- Recombinant Vaccinia CEA (70DD) Vaccine In Low Tumor Burden Colorectal CancerNational Center For Research Resources1998–2000
- Onco Vax CL In Colorectal CancerNational Center For Research Resources1998–2000
- Imaging Trial Of 3622w94National Center For Research Resources1998–2000
- Renovation Of Space In Volker HallNational Center For Research Resources1999
- Bms191352 In Advanced CarcinomaNational Center For Research Resources1997–1999
- Recombinant Tumor Vaccine--CatbrmNational Cancer Institute1996–1999
- Core--Institutional ProtocolsNational Cancer Institute1996–1999
- Core--Developmental FundsNational Cancer Institute1996–1999
- Clinical Trials Of Biological Response Modifiers-Task ANational Cancer Institute1996–1999
- Safety And Pharmacokinetics Of 3622w94National Center For Research Resources1997
- Recombinant Vaccinia-Cea (70DD) Vaccine In Low Tumor Burden AdenocarcinomaNational Center For Research Resources1997
- Completion Of Shell Space For Genetics CenterNational Center For Research Resources1997
- Bms-182248(Br96-Doxorubicin Conjugate) In Patients With Advanced CarcinomaNational Center For Research Resources1997
- Recombinant Rv-Cea In Low Tumor Burden Adenocarcinoma Of The ColonNational Center For Research Resources1996
- R CEA Immunogen In Metastatic Adenocarcinoma Of The BreastNational Center For Research Resources1996
- Bms-182248 In Patients With Advanced CarcinomaNational Center For Research Resources1996
- Clinical Trials Of Biological Response ModifiersDivision Of Cancer Treatment1995–1996
- Tumor Vaccine CatbrmNational Cancer Institute1993–1995
- Monoclonal Antibodies And Other Targeting AgentsDivision Of Cancer Treatment1989–1994
- Cancer Center Core Support GrantNational Cancer Institute1985–1994
- Construction Grant For Rodent Barrier UnitNational Cancer Institute1992
- Human Immune Cytopenias--Monoclonal AntibodiesNational Institute Of Allergy And Infectious Diseases1989–1991
- Radiolabeled Chimeric Monoclonal Antibody (C-17-1a) Colon CancerNational Center For Research Resources1990
- Phase I 131-1 Lym-1 Patients With Diffuse Aggressive LymphomasNational Center For Research Resources1990
- IV 131I Labeled Chimeric Igg4 B72.3 In Advanced Colorectal CarcinomaNational Center For Research Resources1990
- Chimeric Monoclonal Anti-Gd2 Antibody 14.18 In Metastatic MelanomaNational Center For Research Resources1990
- Hematology Training ProgramNational Institute Of Diabetes And Digestive And Kidney Diseases1986–1988
- Human Immune Cytopenias-Studies With Monoclonal AntibodyNational Institute Of Allergy And Infectious Diseases1985–1988
- Melanoma Tumor Detection Using III Inlabeled Monoclonal Antibody Type 96.5National Center For Research Resources1985
- Colon Cancer Tumor Imaging Using Iii-Indium Labeled Monoclonal Antibody Zce 025National Center For Research Resources1985
- Core Facilites--Outpatient Nursing UnitNational Cancer Institute1985
- Cancer Center Core Support Grant (COMPREHENSIVE)National Cancer Institute1985
- Hematology Training ProgramNat Inst Of Arthritis, Diabetes, Digestive &Kidney Diseases1985
